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Abstract
The interaction between schistosomiasis and Salmonella is a particularly important issue in
Africa, where dual infection by the parasite and the bacterium are likely common. In this
review, the ways in which schistosomiasis affects human biology as it relates to Salmonella
are described. Those who are infected by both organisms experience reduced immunologi-
cal functioning, exhibit irreversible organ damage due to prolonged schistosomiasis infec-
tion, and become latent carriers of Salmonella enterica serotypes Typhi and Paratyphi and
S. Typhimurium. The sequestration of the bacteria in the parasite leads to ineffective antibi-
otic treatment because the bacteria cannot be completely killed, and lingering infection may
then lead to antimicrobial resistance. These manifestations are likely not just for those dually
infected but also for those first infected with schistosomes and, later, Salmonella. More data
are needed to better understand dual infection, particularly as it may impact treatment and
prevention of schistosomiasis and Salmonella in sub-Saharan Africa.
Introduction
Substantial progress has been made in reducing the incidence of communicable diseases glob-
ally. In Africa, where the burden of communicable diseases is particularly high, the mortality
rate of children under five years of age has dropped from 173 to 95 per 1,000 live births from
1990 to 2012 [1]. This reduction in deaths among children under five are a result of a combina-
tion of efforts, including increased access to clean water, sanitation, and improved hygiene, as
well as increased rates of immunizations for vaccine-preventable diseases.
There are, however, still a number of preventable diseases that are neglected, including Sal-
monella and schistosomiasis. While each of these diseases has a significant impact on morbid-
ity and mortality in sub-Saharan Africa, coinfection has important implications for country
control and prevention plans. The following review summarizes the current state of knowledge
on the biological interactions between Sal. enterica subtypes Typhi and Paratyphi and invasive
non-typhoidal S. Typhimurium (iNTS) and schistosomiasis, as well as the burden of each in
the context of sub-Saharan Africa.
Burden of Salmonella in Africa
Typhoid and paratyphoid fever are major causes of morbidity and mortality globally, causing
an estimated 21.7 million illnesses and 217,000 deaths annually [2, 3]. Invasive nontyphoidal
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salmonellosis also contributes significantly to the global burden of disease, with an estimated
3.4 million cases and a case fatality rate of 20% [4]. Yet, data specific to the African region are
limited. Salmonella serotypes Typhi (S. Typhi) and Paratyphi A, B, and C, are the best
described serotypes that cause typhoid fever (TF) and paratyphoid fever, respectively [5]. Both
serotypes of the bacteria act by invading the small intestine and entering the bloodstream and
other organs (e.g., the liver and spleen) where they multiply further before re-entering the
bloodstream. Clinical presentation varies from mild-grade fever to abdominal discomfort and
complications including intestinal perforations [6]. Practically, the diagnostic gold standard
generally involves performing a blood culture to isolate the bacteria. Once confirmed, treat-
ment often consists of antibiotics [6]. Relapses can occur in 5%–10% of patients [7].
Despite a clear understanding of disease mechanisms and treatment, lack of diagnostic
capabilities and surveillance systems, among other factors, has made it difficult to accurately
describe the burden of TF (and paratyphoid fever) and iNTS disease in Africa. In 2008, the
World Health Organization (WHO) expressed the need for more epidemiological data to esti-
mate the incidence of Salmonella in Africa [3]. Few studies have characterized the burden in
this region. Mogasale et al. estimates incidence from 123 per 100,000 in West Africa, to 195
per 100,000 in South Africa, to as high as 465 per 100,000 persons in East Africa [8]. A system-
atic review of 25 studies found an incidence of 725 per 100,000 in sub-Saharan Africa [9].
Other country-specific estimates in Africa are similarly within these ranges [10, 11].
African countries will be better able to plan for Salmonella control as new data emerge,
though other challenges will arise. Namely, there is increasing concern in the international com-
munity that infection of parasites, sometimes multiple parasites, may compromise the body’s
ability to deploy a protective response to other acute bacterial or viral infections. Consequently,
immunological responses to control and prevention strategies such as vaccinations may be
attenuated in the presence of other infections commonly found in developing countries [12–14].
Burden of Schistosomiasis in Africa
Africa also suffers from the highest burden of neglected tropical diseases (NTDs), including
schistosomiasis (also known as bilharzia), an infectious chronic disease caused by parasitic
worms found in fresh water [15]. There are five main species of the worm, but Schistosoma
mansoni and S. haematobium are predominantly found in Africa and manifest in the form of
intestinal and urogenital schistosomiasis, respectively [16]. Schistosomiasis ranks second only
to malaria amongst cases of parasite-associated mortality, killing an estimated 280,000 people
annually in Africa alone [17]. In 2013, more than 40 million people were treated for schistoso-
miasis, though at least 261 million people required preventive treatment, >90% of whom live
in Africa [15]. The few schistosomiasis seroprevalence studies that exist indicate that 90% of
those living in high-risk areas will acquire an infection at some point in their lives, which often
occurs before the age of ten. In low-risk areas, between 25% to 40% will be infected by the age
of 35 [18, 19]. Fragile health systems coupled with lack of safe water, sanitation, and hygiene in
many areas throughout Africa make schistosomiasis particularly challenging to control [20].
Clinical underdetection of schistosomiasis is common. The current gold standard diagnos-
tic is microscopic examination of stool or urine for eggs [21], though it is not sensitive enough
to detect mild infections where adult worms have not produced eggs in numbers sufficient for
detection. Some studies have found that upwards of 20%–30% of active infections are missed
in stool or urine samples, as eggs are not always passed into the specimen on the day of testing
[22–24]. Thus, the reported prevalence of schistosomiasis is likely to be an underestimate. By
some estimates, the burden of active cases of schistosomiasis in 2007 may have been between
391 to 587 million people worldwide [12].
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Schistosomiasis can also cause long-term effects beyond the period of active infection. For
example, infections have been found to be significantly associated with anemia, chronic pain,
diarrhea, exercise intolerance, and malnutrition [25]. The parasite causes acute granulomatous
and fibrotic injury to bodily organs that can lead to chronic disability. Based on a meta-analysis
of 135 randomized and observational studies of schistosomiasis, the parasitic infection is asso-
ciated with a number of disability-linked morbidities. Repeated cycles of infection are com-
mon in endemic areas where infection prevention and control measures (including control of
intermediate hosts) are lacking. If left untreated, the worms live within the host for an average
of two to five years. Frequently, however, those at risk of multiple waves of infection will gener-
ally experience active infection for 15 or more years on average [26]. Schistosomiasis can be
treated with praziquantel, which kills the adult worms in the body [27]. Treatment with prazi-
quantel is generally safe, even in those living with decreased immune functioning, such as
those with HIV [28]. Thus, in high transmission areas, WHO recommends that treatment be
repeated yearly for a number of years, and cases monitored to determine treatment effective-
ness. The greatest limitation to schistosomiasis control, however, is availability of praziquantel
[16]. While efforts have been made to improve access, including the use of cheaper generics,
WHO estimates that only 13.1% of people globally who required praziquantel treatment
received it [15]. Lai et al. estimate that 123 million doses of praziquantel are needed per year to
treat school-aged children, and 247 million are needed for all affected populations [29]. While
access to treatment is important, control of schistosomiasis requires a multipronged strategy
that involves interrupting the chain of transmission by ensuring that water is free of parasites
and basic sanitation is adhered to, especially as drug resistance to praziquantel becomes more
of an issue [30, 31].
Interaction between Salmonella and Schistosomiasis
There has been limited information to date of the interaction between Salmonella and schisto-
somiasis. However, evidence suggests that this interaction warrants more attention, especially
as additional evidence emerges about the true burden of typhoid fever and iNTS disease in
Africa [32]. Based on available data, typhoid and schistosomiasis have similar geographic dis-
tributions, and the highest burden of both NTDs falls on children under 15 years of age [18,
19, 33]. While studies do exist that assess the immunological response to schistosomal and Sal-
monella coinfection, most have been conducted on small samples of patients in Egypt and Bra-
zil in the late 1980s [34]. Few studies to our knowledge have been conducted in Africa (see
Table 1) [35–39].
Reduced immunological functioning
Both Salmonella and schistosomal infection can affect liver and kidney function, which can
consequently affect the pharmacokinetics and pharmacodynamics of biological metabolites in
the bloodstream [40–42]. Chronic infection of schistosome eggs trapped in the tissues (most
commonly in the kidney and liver, though may affect other organs as well) leads to the secre-
tion of proteolytic enzymes that provoke inflammatory and granulomatous reactions. Over
time, these reactions inflame the epidermal tissue layer, producing fibrotic deposits that
increase the risk of infection by any number of organisms not limited to Salmonella [43]. What
is unknown, however, is the in vivo nature of the interaction between Salmonella and schisto-
somiasis: Does damage to the liver and kidneys due to schistosomiasis aggravate and prolong
Salmonella infection, or vice versa?
Previous research examined the extent to which liver infection may affect levels of circulat-
ing biochemical compounds in blood serum [34]. In a case-control study of 55 patients (20 of
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Table 1. Summary of studies on interaction between schistosomiasis and Salmonella.
Study Year* Location Number of
Subjects
Ages Schistosomiasis† Salmonella† Main interaction described
Reduced immunological functioning
Higashi GI,
et al.
1975 Egypt 13 12−30 S. mansoni,
S. haematobium
S. Paratyphi A,
S. Typhi
Renal functioning is particularly reduced in patients
with S. mansoni and S. Paratyphi A infections
Carvalho EM,
et al‡
1983 Brazil 38 (15 controls) 3−66 Schistosomiasis Salmonella Incidence of circulating immune complex was
significantly higher in those with chronic
salmonellosis than in patients with schistosomiasis
alone
el-Hawy AM,
et al.
1985 Egypt 55 (20 controls) 15−55 S. mansoni Salmonella Salmonella infection more difficult to treat in chronic
salmonellosis with S. mansoni
Lambertucci
JR, et al.
1988 Brazil 3 5 (n = 1)
14 (n = 2)
S. mansoni Salmonella Clinical evidence of renal lesions due to coinfection
Martinelli R,
et al.
1992 Brazil 16 (divided into 2
groups by
diagnosis)
17.7 (mean
age of
Group I)
23.0 (mean
age of
Group II)
Schistosomiasis Salmonella Prolonged Salmonella infection causes renal
damage that exacerbates pre-existing schistosomal
glomerulopathy
Abdul-Fattah
MM, et al.
1995 Egypt 190 (50 controls) No ages
reported
Schistosomiasis Salmonella Coinfection leads to greater risk of developing
glomerulonephritis, primarily due to prolonged
Salmonella bacteremia
Schistosomiasis patients as latent carriers of Salmonella
Halawani A,
et al.
1960 Egypt 36 (divided into 3
groups by
diagnosis and
treatment)
17−45 S. haematobium Salmonella Chloramphenicol less effective in presence of
urinary schistosomiasis; treating schistosomiasis
first found to increase response to chloramphenicol
Hathout Se-D 1970 Egypt 54 10−50 S. haematobium Salmonella Incidence of typhoid urinary carrier state much
higher in children and young adults than older ages
Young SW,
et al.
1973 Egypt 2 No ages
reported
S. mansoni S. Paratyphi A S. Paratyphi cultured from S. mansoni in patients
with chronic salmonellosis
Franco MM,
et al.
1976 Zimbabwe 142 (divided into 4
groups by
diagnosis)
No ages
reported
S. mansoni,
S. haematobium
S. Typhi Patients with bilharziasis had higher Widal positivity
than those without for Salmonella
Ali OF, et al. 1978 Egypt 200 10−40 S. haematobium S. Typhi Incidence of being an S. Typhi carrier was higher
among schistosomal than non-schistosomal
patients
Gendrel D,
et al.
1984 Gabon 25 3−18 S. intercalatum S. Typhi,
S. Paratyphi A,
B, C
S. intercalatum prolongs Salmonella infection
Igwe NN &
Agbo EA
2014 Nigeria 500 1−26 S. mansoni S. Typhi Strong relationship between Salmonella and S.
mansoni; patients with recurrent enteric fever
should be screened for asymptomatic
schistosomiasis
Mohager MO,
et al.
2014 Sudan 288 6−55 (but
majority 11
−16)
S. mansoni,
S. haematobium
Salmonella Incidence of Salmonella among patients with
schistosomiasis higher in children than adults;
infection incidence high in those in which
schistosomiasis lasted >1 year
Modebe AA,
et al.
2014 Nigeria 250 All ages S. mansoni Salmonella S. mansoni provides place for Salmonella
multiplication before reentering blood stream;
chemotherapy for Salmonella must be administered
with antischistosomal treatment
Salem AK,
et al.
2015 Sudan 203 No ages
reported
S. mansoni,
S. haematobium
Salmonella Direct relationship between schistosomiasis and
Salmonella infection that requires routine screening
in schistosomiasis patients
Animal studies
LoVerde PT,
et al.
1980 Lab-
based
Hamsters N/A S. mansoni,
S. haematobium,
S. japonicum
S. Typhimurium Pili on S. Typhi attaches to schistosome’s digestive
opening; nonpiliated may also attached (but
reduced rate)
Melhem RF,
et al.
1983 Lab-
based
Hamsters N/A S. mansoni S. Typhimurium Pili on S. Typhi attaches to schistosome’s digestive
opening; Salmonella found to only colonize
digestive tract due to glycolipids on surface of worm
that allows binding
(Continued)
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whom were normal controls), El-Hawy et al. found that phagocytosis, a major mechanism
within the body’s immune system for removing pathogens and micro-organisms, was affected
depending on the patient’s condition. Patients with noncomplicated typhoid who were treated
with chloramphenicol exhibited increased phagocytic behavior when compared to normal
controls. After the chloramphenicol course, however, phagocytic function did not normalize,
but instead was depressed below normal values, suggesting that the drug may affect phagocyto-
sis. Conversely, patients with chronic salmonellosis and S. mansoni (treated with ampicillin
and praziquantel, respectively), and patients with hepatosplenic schistosomiasis and active S.
mansoni (treated with only praziquantel) had depressed levels of phagocytosis—an indication
that schistosomiasis may have altered the body’s immune response. Chronic Salmonella infec-
tion was found to be more difficult to treat in the group with S. mansoni. Though the mecha-
nism is not fully understood, this may be due to a combination of factors, including
multiplication of the Salmonella organism hiding within the schistosome and/or altered
immune responses that more easily allow the bacteria to multiply inside the reticuloendothelial
system cells [34]. More data are needed to better understand how differing antibiotic and anti-
parasitic treatment regimens affect coinfected patients.
There have also been few studies on coinfection of Salmonella and schistosomes that suggest
that presence of both conditions further worsens renal function. One Brazilian study analyzed
renal involvement of eight patients with hepatosplenic schistosomiasis and prolonged Salmo-
nella infection compared to eight patients with schistosomal glomerulopathy (a reduction of
the ability of the kidneys to flush out physiologic byproducts from the bloodstream). The
authors found that prolonged Salmonella infection exacerbates pre-existing schistosomal glo-
merulopathy due to renal damage caused by the prolonged infection [44]. At least one other
study has corroborated this finding: patients with coinfection of both Salmonella and schisto-
somiasis had a greater risk of developing glomerulonephritis, primarily due to Salmonella anti-
gens [45].
Schistosomiasis patients as latent carriers of Salmonella
Typhoid fever and iNTS disease have also been found to recur until schistosomiasis is treated,
leading some researchers to hypothesize that Salmonella is able to persist in the body by attach-
ing to the schistosome. Because of this purported relationship, the Salmonella are protected
from antibacterial drugs [46–48].
In one of the earliest studies, Young et al. collected S. mansoni worms from patients with
salmonellosis. The samples cultured from the tegument of the worms tested positive for S.
Paratyphi A. The authors concluded that there exists a symbiotic relationship between
Table 1. (Continued)
Study Year* Location Number of
Subjects
Ages Schistosomiasis† Salmonella† Main interaction described
Tuazon CU,
et al.
1985 Lab-
based
Mice N/A S. mansoni S. Typhimurium Salmonella bacteremia (regardless of presence of
pili) increased mortality rate of mice infected with S.
mansoni; praziquantel administration prior to S.
Typhi challenge prolonged survival
* Year indicated is year of manuscript publication; no journals indicated the year of data collection, with the exception of the following: Igwe NN & Agbo EA
[2012], Salem AK, et al. [2005]
† If subtype mentioned, then identified here; if not, only genus named
‡ Carvalho et al. also included 18 patients who were dually infected with schistosomiasis and Leishmaniasis (but not Salmonella)
doi:10.1371/journal.ppat.1005928.t001
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Salmonella and schistosomes that make dual infection in humans particularly difficult to diag-
nose and treat [49].
Similar observations have also been made with other species of Schistosoma. Expanding on
our understanding of this association, LoVerde et al. used some strains of Salmonella Typhi-
murium, a serotype that infects humans as well as some animals, that contained a mutated
gene and thus did not express pili (the hair-like appendage found on the surface of bacteria)
[50]. Other strains did express pili. Hamsters were infected with various strains of S. mansoni,
S. haematobium, and S. japonicum and then sacrificed to remove the adult schistosomes. A
subset of the worms’ digestive openings was ligatured to test whether Salmonella was associ-
ated with the host’s gut and/or with the surface tegument of the worm. The experiment
revealed that S. Typhimurium was associated with each of the Schistosoma tested with the pres-
ence of either the pili or the worm’s ligature, though a greater proportion of female worms
tested positive for Salmonella than did male worms. The presence of both the pili and worm’s
ligature increased the likelihood of adhesion between bacterium and parasite when compared
to the presence of just one of the appendages. Nevertheless, the study concluded that the pili of
the Salmonella bacterium, as well as the worm’s digestive tract opening, may play an important
role in adhesion of Salmonella to the parasite.
This finding was supported by an in vitro experiment that demonstrated that pili expression
of the S. Typhimurium bacterium is important for attaching to the surface tegument of S. man-
soni. In samples without pili, Salmonella was found to only colonize the digestive tract, as
opposed to colonizing both the surface tegument (specifically to the mannose-like receptors)
and the digestive tract in samples with pili. The mannose-like receptors that bind to mannose,
a sugar monomer, were suspected to be glycolipids on the surface of the worms that allow for
the binding of the pili of Salmonella. This was further confirmed by treating S. Typhimurium
with antipili antibodies prior to incubation with schistosomes. Because the pili were blocked
by antibodies, no bacterial agglutination was observed on the surface of the schistosomes [51].
Tuazon et al. also studied the importance of pili in mice. Mice were infected initially with S.
mansoni; a subset was then either challenged with piliated or nonpiliated S. Typhimurium.
These mice were compared to another set that was administered praziquantel prior to the S.
Typhimurium challenge. While mice challenged with nonpiliated bacterium compared to
piliated had longer survival times, there was no significant difference in the mortality rates of
the mice. However, the study demonstrated that Salmonella—regardless of pili presence—
increased the mortality rate of mice infected with S. mansoni. Praziquantel administration
prior to S. Typhimurium challenge prolonged survival significantly [52]. More studies in
humans are needed to better understand the relationship, as well as how the relationship may
affect treatment options and detection of schistosomiasis and Salmonella.
The synergistic parasite–bacterium relationship in hamsters and mice has been shown in
human hosts as well. A number of other studies in Egypt and in Africa have also characterized
the relationship between schistosomal infections and urinary typhoid carriers. Because the
schistosome eggs cause fibrotic lesions in the urinary tract, typhoid urinary tract infections are
persistent and often lead to patients becoming chronic typhoid carriers [35, 53–56]. In one
study, patients who were persistent urinary carriers of Salmonella did not initially respond to
chloramphenicol treatment. Following treatment for bilharzia, however, a second course of
the same antibiotic was administered and Salmonella was no longer found in urine cultures
[55]. Similarly, a study in Gabonese children found that relapse of Salmonella infection only
occurred in children who were not first treated with niridazole or oltipraz for S. interaclatum
(species that is localized in the colon and rectum). Whether antischistosomal treatment was
administered appeared to affect the response to chloramphenicol or ampicillin treatment for
Salmonella [35]. It will also be important to understand whether protected Salmonella bacteria
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residing inside the schistosomes are shielded from the effects of antibacterial drugs, thereby
avoiding the development of drug resistance.
Studies in Nigeria and Sudan have also found a strong, direct relationship between coinfec-
tion with Salmonella and either S. haematobium or S. mansoni [36–39]. One of the studies in
Sudan found that the incidence of Salmonella was higher among children than adults with
schistosomiasis, and that the incidence even increased if an individual (regardless of age) had
schistosomiasis for more than a year [37]. As a result of these findings, the authors of these
four African studies conclude that patients with recurrent enteric fever living in schistosomia-
sis endemic regions should also be routinely screened for asymptomatic schistosomiasis. Mod-
ebe et al. went further to recommend that chemotherapy for Salmonella be administered prior
to antischistosomal treatment, as the schistosome creates a place for the Salmonella bacterium
to multiply before re-entering the bloodstream [38].
Discussion
The present review suggests an interaction between Salmonella and schistosomiasis that will be
important to explore further. In spite of the limited number of studies, infection with schisto-
somes may lead to irreversible damage and residual fibrotic deposits in organs that make one
more susceptible to Salmonella infections. Further, parasitic infection reduces immunological
functioning that makes it more difficult for the body to combat other harmful pathogens,
including Salmonella. Proper treatment for schistosomes would be advisable prior to further
treatment for Salmonella both to ensure the effectiveness of medications in eliminating the
infection, as well as to prevent further drug resistance. Though, based on the limited evidence,
it is not yet clear what the optimal time interval is between infection, treatment, and recovery
from either pathogen. For example, a patient is receiving antibiotics for typhoid fever and is
infected with schistosomiasis before the course of antibiotics has been completed. Is there a
point at which the bacterial load is low enough that the two pathogens do not interact?
These findings have several implications for patients who are coinfected with typhoid and
schistosomiasis. Firstly, if a schistosomiasis patient is diagnosed and treated for typhoid using
antibiotics, treatment may not be complete—and may inadvertently lead to further resistance
in strains of Salmonella. Treatment using first-line antibiotics for many S. Typhi strains has
been decreasing in effectiveness, and many options are no longer available [57–60]. Secondly,
incomplete treatment for Salmonella due to the schistosome’s shielding effect may give rise to
a host of other bacteria control issues and health complications. As the study in Gabonese chil-
dren discovered, the hidden bacteria residing in the schistosome may be shed, leading to a
relapse of Salmonella. Consequently, a drug-resistant Salmonella strain may proliferate by
spreading resistant genes to drug-sensitive bacteria over a prolonged period, resulting in an
infection that is much more difficult to treat. Along similar lines, if an individual is coinfected,
but unaware of coinfection, and received praziquantel as part of a periodic mass drug adminis-
tration campaign, it is plausible that killing the schistosomes could lead to a systemic release of
hidden Salmonella, giving rise to typhoid illness.
As part of its position paper in 2008, WHO recommended that typhoid fever vaccination
programs be implemented in the context of other efforts to control the disease [3]. These deci-
sions should be made based on knowledge of the local epidemiology of typhoid—and based on
the present review, should also include an understanding of the impact of the interactions
between typhoid and other possible pathogens such as schistosomiasis. Despite the availability
of licensed typhoid vaccines that offer protection against S. Typhi and some Paratyphi, one of
which is prequalified by WHO, the number of countries that have incorporated typhoid vac-
cines into their vaccination programs remains low due to the short efficacy of the vaccines
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(three years) [61] and the fact that those polysaccharide vaccines cannot be administered to
children over two years of age. There is currently no vaccine against the NTS subtypes. Based
on the current body of knowledge, it is difficult to conclude whether the effectiveness of a
typhoid vaccine would be diminished if adequate treatment and prevention of parasitic infec-
tions are not first provided [13]. However, there have been studies that have shown evidence
of the reduced protective immune response from vaccines (e.g., tuberculosis, tetanus), in the
presence of schistosomiasis [62–64]. There is also no research to our knowledge on whether
typhoid vaccination can reduce or stop shedding of Salmonella in existing typhoid patients—
though typhoid vaccine manufacturers recommend against vaccinating chronic typhoid carri-
ers and individuals with acute infection [65]. Theoretically, vaccinating a typhoid carrier
where the Salmonella bacterium’s pili is attached to the digestive tract of the worm would most
likely not reduce shedding, as it is hidden from the antibodies produced. Consequently, if the
vaccine is used in populations with a high burden of typhoid, the continual shedding of the
bacterium in spite of vaccination may make the vaccine appear less effective. Understanding
the incidence of coinfection between typhoid and schistosomiasis may help in better targeting
the typhoid vaccine by prioritizing populations whose immune response would not be com-
promised by a concurrent schistosomiasis infection.
These key implications must be better understood and assessed. Further coordinated action
is needed to improve typhoid surveillance, regulating and promoting appropriate use of antibi-
otics, and strengthening infection control and prevention plans. While typhoid conjugate vac-
cines are on the horizon that elicit longer-term protection and can be given to children over
two years of age, the most promising vaccine in the pipeline is, at best, two years away from
WHO prequalification and widespread use [66]. If we are to have realistic plans for deploying
future typhoid vaccines to high-risk populations, we must first understand the true burden of
the co-occurrence of Salmonella and schistosomiasis and how the interaction between them
impacts transmission dynamics.
By using existing surveillance infrastructures in sub-Saharan Africa, we have the opportu-
nity now to study these coinfections in more detail [67]. This is necessary for governments to
prioritize interventions—such as vaccine programs and treatment options—that reduce mor-
bidity and mortality. Particularly for children that suffer the highest burdens of both patho-
gens, breaking the cycle of chronic infection and reinfection with schistosomiasis in order to
treat Salmonella ensures that children can be healthy enough to go to school and develop phys-
ically and mentally in this early stage of life. Schistosomiasis in children has been documented
to lead to disabilities including anemia [25], which leads to stunted growth, and poorer short-
term memory and mental abilities [68, 69]. Furthermore, because children with schistosomia-
sis are also likely to live in regions with other endemic helminths and infectious diseases (e.g.,
malaria), expanding surveillance of other endemic infections in the African region would pro-
vide additional opportunities to study the epidemiology of dual- and multipathogen infections.
Indeed, some of the studies reviewed found that children and young adults were more likely to
be Salmonella carriers than older adults [37, 56]. Though beyond the scope of the present
review, the interaction between Salmonella and schistosomiasis reviewed herein suggests that
parasitisms other than schistosomiasis (e.g., lymphatic filariasis, onchocerciasis, loa loa, and
other soil-transmitted helminth infections) may have similarly unexplored interactions with
Salmonella. Because treatment for schistosomiasis and other parasites often overlap, careful
consideration should be given to the timing of all antihelmintic treatments.
By studying the combined impact of schistosomiasis and typhoid in Africa, policymakers
will be better equipped to understand the nature of the interaction. While this is only one com-
ponent of comprehensive schistosomiasis and typhoid prevention and control programs, addi-
tional data will help ministries of health better target interventions, such as improvements to
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water, sanitation, and hygiene to cut parasitic and bacterial transmission, praziquantel treat-
ment programs, and targeted vaccinations (for both NTDs). Further, comprehensive strategies
that consider the developmental impacts of chronic schistosomiasis will prevent needless pro-
longed suffering from salmonellosis.
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